|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026549,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0037633,
umls-concept:C0066814,
umls-concept:C0150097,
umls-concept:C0242402,
umls-concept:C0355800,
umls-concept:C0439655,
umls-concept:C0596545,
umls-concept:C0991505,
umls-concept:C1280500,
umls-concept:C1382100,
umls-concept:C1696465,
umls-concept:C1706077,
umls-concept:C2934985
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-11-5
|
|
pubmed:abstractText |
Given the dual public health challenges of undertreated pain and opioid abuse, there is a need to reduce attractiveness of opioid analgesics to drug abusers. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules, indicated for treatment of chronic, moderate to severe pain, contain polymer-coated pellets of morphine, each with a core of sequestered naltrexone intended for release only upon tampering (crushing). The purpose of this study was to assess the pharmacodynamic effects (including drug-liking and euphoria) of whole and crushed ALO-01 versus morphine sulfate solution (MSS) and placebo.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1173-2563
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
777-90
|
|
pubmed:dateRevised |
2011-8-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19888784-Adult,
pubmed-meshheading:19888784-Analgesics, Opioid,
pubmed-meshheading:19888784-Capsules,
pubmed-meshheading:19888784-Cross-Over Studies,
pubmed-meshheading:19888784-Delayed-Action Preparations,
pubmed-meshheading:19888784-Double-Blind Method,
pubmed-meshheading:19888784-Drug Combinations,
pubmed-meshheading:19888784-Euphoria,
pubmed-meshheading:19888784-Female,
pubmed-meshheading:19888784-Humans,
pubmed-meshheading:19888784-Male,
pubmed-meshheading:19888784-Middle Aged,
pubmed-meshheading:19888784-Morphine,
pubmed-meshheading:19888784-Naltrexone,
pubmed-meshheading:19888784-Narcotic Antagonists,
pubmed-meshheading:19888784-Pharmaceutical Solutions,
pubmed-meshheading:19888784-Pupil,
pubmed-meshheading:19888784-Time Factors,
pubmed-meshheading:19888784-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
|
|
pubmed:affiliation |
Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc., Bridgewater, New Jersey, USA. beatrice.setnik@kingpharm.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
